Literature DB >> 2556353

Herpes simplex virus stromal keratitis is not titer-dependent and does not correlate with neurovirulence.

D R Grau1, R J Visalli, C R Brandt.   

Abstract

We developed a murine model of ocular herpes simplex virus (HSV) disease which is particularly suited for testing stromal keratitis because most animals show some evidence of infection. Using this model, we characterized the ocular disease patterns caused by ten recent low-passage clinical isolates of HSV-1, as well as those caused by the established laboratory strains HSV-1 KOS and HSV-2 333. Viral strains were evaluated for their ability to cause stromal keratitis, blepharitis, vascularization of the cornea, and mortality. The model was not useful for scoring epithelial keratitis. The ocular disease caused by the recent isolates ranged from very mild disease to severe stromal keratitis. Some of the recent isolates caused disease as severe as the two laboratory strains. A comparison of the virulence characteristics expressed by various HSV strains indicated that the ability to cause stromal disease was correlated with vascularization of the cornea (correlation coefficient = 0.797, P less than 0.001) and was not correlated with the neurovirulence of the strains (correlation coefficient 0.045, P greater than 0.05). The severity of stromal keratitis was not dependent on the amount of inoculum over the range tested and a strain causing severe stromal keratitis caused severe ocular disease even when mixed with a nonstromal strain at ratios of 10:1, 100:1, and 1000:1.

Entities:  

Mesh:

Year:  1989        PMID: 2556353

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  30 in total

1.  Pathogenesis of herpes simplex virus type 1-induced corneal inflammation in perforin-deficient mice.

Authors:  E Chang; L Galle; D Maggs; D M Estes; W J Mitchell
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Sequence variation in the herpes simplex virus U(S)1 ocular virulence determinant.

Authors:  Aaron W Kolb; Timothy R Schmidt; David W Dyer; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-28       Impact factor: 4.799

3.  Multiplex sequencing of seven ocular herpes simplex virus type-1 genomes: phylogeny, sequence variability, and SNP distribution.

Authors:  Aaron W Kolb; Marie Adams; Eric L Cabot; Mark Craven; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-25       Impact factor: 4.799

4.  Inhibition of herpes simplex virus type 1 infection by cationic beta-peptides.

Authors:  Radeekorn Akkarawongsa; Terra B Potocky; Emily P English; Samuel H Gellman; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

5.  Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.

Authors:  C R Brandt; B Spencer; P Imesch; M Garneau; R Déziel
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells.

Authors:  Inna V Larsen; Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2010-10-28       Impact factor: 2.671

7.  Genomic, phylogenetic, and recombinational characterization of herpes simplex virus 2 strains.

Authors:  Aaron W Kolb; Inna V Larsen; Jacqueline A Cuellar; Curtis R Brandt
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

8.  Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application.

Authors:  Marianne Berdugo; Inna V Larsen; Claire Abadie; Catherine Deloche; Laura Kowalczuk; Elodie Touchard; Richard Dubielzig; Curtis R Brandt; Francine Behar-Cohen; Jean-Marc Combette
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

9.  Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps.

Authors:  Monica M Sauter; Joshua J L Gauger; Curtis R Brandt
Journal:  Antiviral Res       Date:  2014-07-01       Impact factor: 5.970

10.  A cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo.

Authors:  Gilbert G Jose; Inna V Larsen; Joshua Gauger; Erica Carballo; Rebecca Stern; Rachel Brummel; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-05       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.